Post-Marketing Surveillance Study: 12 To 24 Weeks Study On The Treatment Emergent Adverse Events In Patients With Type 2 Diabetes Taking Exenatide In Korea

NCT02090673 · Completed

Last updated 2026-05-28

This study tracks side effects in adults with type 2 diabetes who take Exenatide over 12 to 24 weeks in Korea.

Status Completed The study has finished.

Type Observational

Participants 1,711 people

Who can join Ages 18+ · all sexes

Timeline Started 2009-02 · est. completion 2014-03

Where 1 site · South Korea

What this study is testing ClinicalTrials.gov NCT02090673 ↗

Description as written by the study sponsor.

The objective of this regulatory Post-Marketing Surveillance in Korea is to reconfirm the clinical usefulness of Exenatide through collecting, reviewing, identifying and verifying the safety and effectiveness information about Exenatide in general practice.

Treatments tested

Exenatide Drug

Main thing measured	The proportion of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) in patients who are treated with Exenatide for type 2 diabetes mellitus
Sponsor	AstraZeneca
Conditions studied	Diabetes Mellitus Type 2
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02090673 ↗